# Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy

> **NCT04800978** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 37 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** BAVC-C+Durvalumab

## Key facts

- **NCT ID:** NCT04800978
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-14
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-08-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2021-03-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04800978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04800978, "Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04800978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*